4 views left Get unlimited views with a free account

Explore the latest trends and actionable insights on the Sezary Syndrome Pipeline Drugs to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Sezary Syndrome by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 42 ongoing clinical trials involving Sezary Syndrome
Of the 42 trials,22 trials are in Phase II
Furthermore, 9 trials are in Phase I

Number of ongoing Clinical Trials (for drugs) involving Sezary Syndrome by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Sezary Syndrome, an oncology indication. The largest number of ongoing clinical trials for Sezary Syndrome is conducted in North America. Europe and Asia-Pacific are among some of the other prominent regions engaged in Sezary Syndrome-related drug trials.

National Cancer Institute US: The leading ongoing Sezary Syndrome related clinical trial sponsor

National Cancer Institute US is the top sponsor for Sezary Syndrome-related ongoing clinical trials.

Memorial Sloan Kettering Cancer Center, Mayo Clinic, UNC Lineberger Comprehensive Cancer Center, and Sidney Kimmel Cancer Center at Thomas Jefferson University are among other notable clinical trial sponsors involved in Sezary Syndrome. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Sezary Syndrome

Mogamulizumab (Poteligeo), Interferon gamma-1a (Imunomax Gamma), and Prednisolone (Solu-Decortin H, Decortin, Decortin-H, Solu-Dacortin) are among the key marketed drugs involving Sezary Syndrome.

Mogamulizumab (Poteligeo) is a humanized monoclonal antibody targeting C-C chemokine receptor 4 (CCR4). It functions via Cytotoxic To Cells Expressing C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) mechanism of action. It is designed by utilizing the company's Potelligent technology platform. It is formulated as solution and concentrate solution for intravenous route of administration. Poteligeo is indicated for the treatment of CCR4 positive adult T cell leukemia, lymphoma. It is also indicated for recurrent or refractory CCR4 positive peripheral T cell lymphoma and skin T-cell lymphoma. It is also indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sezary syndrome (SS) after at least one prior systemic therapy. Mogamulizumab was first approved in 2012 and is marketed globally including the US, the UK, France, Canada, and China by Kyowa Kirin Co Ltd.

Interferon gamma-1a (Imunomax Gamma) is a recombinant belongs to the class of immunomodulators with antiviral properties. It functions via Interferon Gamma Receptor (IFNGR) Agonist mechanism of action. It is formulated as powder for solution for intravenous route of adminstration. Imunomax Gamma is indicated for the treatment of renal cancer, frequency and reduce the severity of severe infections associated with chronic granulomatous disease, mycosis fungoidesis, and sezary syndrome. Interferon gamma-1a was first approved in 1989 and is marketed in Japan by Kyowa CritiCare Co Ltd.

Explore the latest trends and actionable insights on the Sezary Syndrome Pipeline Drugs to inform business strategy and pinpoint opportunities and risks. Explore the latest trends and actionable insights on the Sezary Syndrome Pipeline Drugs to inform business strategy and pinpoint opportunities and risks. Visit Report Store